Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy

Next Previous
Trial Profile

A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOM-Ev
  • Sponsors United Therapeutics Corporation

Most Recent Events

  • 21 Apr 2025 According to an United Therapeutics Corporation Media Release, data from this study will be presented at the at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025.
  • 06 Dec 2023 Results of three additional years of open-label observation after the close of the placebo-controlled, event-driven study, associated with improved survival in FREEDOM-EV and its Open-Label Extension published in the Advances in Therapy
  • 24 May 2023 Results performing time to first adjudicated clinical worsening (CW) event using Win Ratio Analysis , presented at the 119th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top